Regulators adopt more orphan drugs.
作者信息
Reardon Sara
出版信息
Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.
DOI:10.1038/508016a
PMID:24695293
Abstract
摘要
相似文献
1
Regulators adopt more orphan drugs.监管机构批准了更多孤儿药。
Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.
2
Duel over discounts. Pharma, providers at odds over 'orphan drugs'.折扣之争。制药公司与供应商在“孤儿药”问题上存在分歧。
Mod Healthc. 2012 Jan 23;42(4):30-1.
3
The Orphan Drug Act Revisited.《孤儿药法案》再探讨。
JAMA. 2019 Mar 5;321(9):833-834. doi: 10.1001/jama.2019.0290.
4
Orphanage at the FDA.美国食品药品监督管理局的孤儿药管理部门
J Cardiovasc Transl Res. 2012 Oct;5(5):735-6. doi: 10.1007/s12265-010-9242-2. Epub 2010 Nov 16.
5
Rare diseases, orphan drugs, and orphaned patients.罕见病、孤儿药与被忽视的患者。
Mol Interv. 2006 Aug;6(4):186-91. doi: 10.1124/mi.6.4.2.
6
Rare diseases, orphan drugs and their regulation: questions and misconceptions.罕见病、孤儿药及其监管：问题与误区。
Nat Rev Drug Discov. 2010 Dec;9(12):921-9. doi: 10.1038/nrd3275. Epub 2010 Nov 9.
7
8
Law and research could add up to profitable niche drugs.法律与研究相结合有望催生有利可图的小众药物。
Nature. 2007 Apr 19;446(7138):856. doi: 10.1038/446856b.
9
The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.《孤儿药法案》对罕见病神经学产品的开发和进步的影响：描述性综述。
Clin Pharmacol Ther. 2010 Oct;88(4):449-53. doi: 10.1038/clpt.2010.193.
10
A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.中、美、欧、日均出台孤儿药政策，如何走出中国式孤儿药之路：跨国比较研究
J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.
引用本文的文献
1
Capture and passive predation in times of COVID-19 pandemic.新冠疫情时期的捕获与被动捕食
Public Choice. 2022;193(3-4):163-186. doi: 10.1007/s11127-022-01005-0. Epub 2022 Oct 8.
2
Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.孤儿药认定在癌症治疗中的应用（2008-2017 年）：美国和欧盟的综合比较分析。
BMJ Open. 2019 Oct 10;9(10):e028634. doi: 10.1136/bmjopen-2018-028634.
3
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.欧美仿制药市场比较：价格、销量与支出
Milbank Q. 2017 Sep;95(3):554-601. doi: 10.1111/1468-0009.12279.
4
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.生物标志物定义的常见疾病亚组：《孤儿药法案》覆盖范围的政策与经济影响
PLoS Med. 2017 Jan 3;14(1):e1002190. doi: 10.1371/journal.pmed.1002190. eCollection 2017 Jan.
5
FDA Policy and Cardiovascular Medicine.美国食品药品监督管理局政策与心血管医学
Circulation. 2015 Sep 22;132(12):1136-45. doi: 10.1161/CIRCULATIONAHA.114.010295.
6
How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012.在英国上市的新药创新程度如何？对《英国国家处方集》（BNF）2001 - 2012年列出的新药进行的回顾性研究。
BMJ Open. 2014 Oct 24;4(10):e006235. doi: 10.1136/bmjopen-2014-006235.
Zotero 插件